Skip to main content

Tourette Syndrome

15
Pipeline Programs
13
Companies
23
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
11
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Emalex Biosciences
Emalex BiosciencesIL - Chicago
2 programs
1
1
EcopipamPhase 31 trial
EcopipamPhase 21 trial
Active Trials
NCT04007991Completed153Est. Sep 2021
NCT06021522Active Not Recruiting150Est. Mar 2027
Otsuka
OtsukaJapan - Tokushima
1 program
1
Aripiprazole Oral SolutionPhase 31 trial
Active Trials
NCT03487783Completed121Est. Feb 2020
Neurocrine Biosciences
8 programs
1
7
NBI-98854Phase 21 trial
NBI-98854Phase 21 trial
NBI-98854Phase 21 trial
ValbenazinePhase 21 trial
ValbenazinePhase 21 trial
+3 more programs
Active Trials
NCT02256475Completed36Est. Dec 2015
NCT02581865Completed124Est. Dec 2016
NCT03732534Terminated6Est. Feb 2019
+5 more trials
Medtronic
MedtronicNJ - Phillipsburg
2 programs
1
Thalamic deep brain stimulationPhase 21 trial
Continuous DBSN/A1 trial
Active Trials
NCT02056873Completed10Est. Aug 2023
NCT00311909Completed5Est. Apr 2006
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD5213 and placeboPhase 21 trial
Active Trials
NCT01904773Completed29Est. Feb 2015
Noema Pharma
Noema PharmaSwitzerland - Basel
1 program
1
GemlapodectPhase 21 trial
Active Trials
NCT06315751Active Not Recruiting164Est. Jun 2026
Pins Medical
Pins MedicalChina - Beijing
1 program
1
deep brain stimulationPhase 11 trial
Active Trials
NCT02253498Unknown20Est. Dec 2018
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
pramipexole immediate releasePHASE_21 trial
pramipexole 0.125 mg BIDPHASE_31 trial
Active Trials
NCT00558467Completed63
NCT00681863Terminated45
Teva
TevaIsrael - Petach Tikva
2 programs
TEV-50717PHASE_31 trial
TEV-50717PHASE_31 trial
Active Trials
NCT03571256Completed158Est. Dec 2019
NCT03567291Terminated228Est. May 2020
Ipsen
IpsenChina - Tianjin
1 program
Abobotulinum toxin AN/A1 trial
Active Trials
NCT02187679Unknown30
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Active TreatmentN/A1 trial
Active Trials
NCT03642951WithdrawnEst. Jun 2022
Alliance Pharmaceuticals
1 program
Deep Brain StimulationN/A1 trial
Active Trials
NCT06388291Completed18Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Emalex BiosciencesEcopipam
TevaTEV-50717
TevaTEV-50717
OtsukaAripiprazole Oral Solution
Boehringer Ingelheimpramipexole 0.125 mg BID
Noema PharmaGemlapodect
Emalex BiosciencesEcopipam
Neurocrine BiosciencesNBI-98854
Neurocrine BiosciencesValbenazine
Neurocrine BiosciencesValbenazine
Neurocrine BiosciencesValbenazine
Neurocrine BiosciencesValbenazine
Neurocrine BiosciencesNBI-98854
Neurocrine BiosciencesNBI-98854
AstraZenecaAZD5213 and placebo

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 1,906 patients across 23 trials

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Start: Aug 2023Est. completion: Mar 2027150 patients
Phase 3Active Not Recruiting

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

Start: May 2018Est. completion: Dec 2019158 patients
Phase 3Completed

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Start: May 2018Est. completion: May 2020228 patients
Phase 3Terminated
NCT03487783OtsukaAripiprazole Oral Solution

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

Start: May 2018Est. completion: Feb 2020121 patients
Phase 3Completed
NCT00681863Boehringer Ingelheimpramipexole 0.125 mg BID

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Start: May 200845 patients
Phase 3Terminated

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

Start: Sep 2024Est. completion: Jun 2026164 patients
Phase 2Active Not Recruiting

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

Start: Jun 2019Est. completion: Sep 2021153 patients
Phase 2Completed

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Start: Oct 2018Est. completion: Feb 20196 patients
Phase 2Terminated

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Start: Apr 2018Est. completion: Jul 201981 patients
Phase 2Terminated

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Start: Feb 2018Est. completion: Jul 201985 patients
Phase 2Completed

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Start: Oct 2017Est. completion: Nov 2018127 patients
Phase 2Completed

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

Start: Jul 2016Est. completion: Nov 2017155 patients
Phase 2Completed

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Start: Mar 2016Est. completion: Apr 201798 patients
Phase 2Completed

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Start: Nov 2015Est. completion: Dec 2016124 patients
Phase 2Completed
NCT01904773AstraZenecaAZD5213 and placebo

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

Start: Aug 2013Est. completion: Feb 201529 patients
Phase 2Completed
NCT00558467Boehringer Ingelheimpramipexole immediate release

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

Start: Jan 200863 patients
Phase 2Completed
NCT00311909MedtronicThalamic deep brain stimulation

Thalamic Deep Brain Stimulation for Tourette Syndrome

Start: Jun 2005Est. completion: Apr 20065 patients
Phase 2Completed
NCT02253498Pins Medicaldeep brain stimulation

The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome

Start: Dec 2016Est. completion: Dec 201820 patients
Phase 1Unknown

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Start: Sep 2014Est. completion: Dec 201536 patients
Phase 1Completed

Deep Brain Stimulation in Tourette Syndrome

Start: Aug 2022Est. completion: Jun 202518 patients
N/ACompleted

Multi-site Transcranial Magnetic Stimulation Therapy of the Supplementary Motor Area in Children With Tourette Syndrome

Start: Jul 2019Est. completion: Jun 2022
N/AWithdrawn
NCT02056873MedtronicContinuous DBS

Tourette Syndrome Deep Brain Stimulation

Start: Mar 2014Est. completion: Aug 202310 patients
N/ACompleted
NCT02187679IpsenAbobotulinum toxin A

Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome

Start: Jan 201430 patients
N/AUnknown

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.